comparemela.com

Latest Breaking News On - Li jianyong - Page 1 : comparemela.com

AstraZeneca Calquence approved in China for chronic lymphocytic leukaemia

Cambridge: AstraZeneca’s Calquence (acalabrutinib), a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in China for the treatment of adult patients with chronic.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.